^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecentriq (atezolizumab)

    i
    Other names: MPDL3280A, RG7446, RO5541267, MPDL-3280A, RG-7446, RO 5541267, RO 554-1267, RG7446-42, RO-5541267, MPDL 3280A, RG 7446, RG744642, RG 744642, RG-744642, RO-5541267 IV, MPDL 3280A IV
    Company:
    Roche
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    1d
    Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (clinicaltrials.gov)
    P2, N=54, Completed, Hospices Civils de Lyon | Unknown status --> Completed | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • ipatasertib (RG7440)
    1d
    Targeted immunotherapy and tumor immunogenicity in liver transplant recipients: A study on lenvatinib and PD-L1 inhibition. (PubMed, Pak J Pharm Sci)
    This combination shows promising effects and good safety in patients with HCC who have received liver transplants. Such a method offers a fresh choice for treating those who are thought not to be suitable for immunotherapy, so it needs to be tested in more extensive controlled research.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    Tecentriq (atezolizumab) • sorafenib • Lenvima (lenvatinib)
    2d
    First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies. (PubMed, J Immunother Cancer)
    Alomfilimab treatment was associated with an acceptable safety profile across both mono and combination approaches, accompanied by decreased ICOS+Tregs populations and enhanced CD4+ and CD8+ effector T cells cell activity. Limited clinical activity was observed despite evidence of biological activity.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    5d
    Immuno-MESODEC: Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P1/2, N=15, Recruiting, University Hospital, Antwerp | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    WT1 (WT1 Transcription Factor)
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    5d
    Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, University of Oklahoma | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    5d
    Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model. (PubMed, Health Technol Assess)
    Sequences starting with atezolizumab + bevacizumab + doublet platinum chemotherapy had similar costs and quality-adjusted life-years to sequences starting with pembrolizumab + doublet platinum chemotherapy. Sequences starting with pemetrexed + platinum chemotherapy had the lowest costs but also the lowest total quality-adjusted life-years...46. See the NIHR Funding and Awards website for further award information.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • pemetrexed
    6d
    Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=550, Not yet recruiting, SystImmune Inc.
    New P3 trial
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin)
    7d
    Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma. (PubMed, Liver Cancer)
    This dissociation between PFS and OS may reflect differences in disease biology, treatment sequencing, and post-progression management rather than intrinsic superiority of either regimen. These findings highlight the importance of individualized treatment selection and careful consideration of tumor characteristics and hepatic reserve when choosing first-line immunotherapy for uHCC.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    AFP (Alpha-fetoprotein)
    |
    AFP elevation
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    7d
    Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study. (PubMed, Thorac Cancer)
    Systemic inflammation, as assessed by CRP level, may modify the efficacy of bevacizumab in advanced non-squamous NSCLC. These hypothesis-generating findings warrant prospective validation to clarify the role of CRP in treatment stratification.
    Retrospective data • Journal
    |
    CRP (C-reactive protein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    7d
    Acclaim-3: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (clinicaltrials.gov)
    P1/2, N=62, Recruiting, Genprex, Inc. | Trial primary completion date: Feb 2026 --> Jun 2026
    Trial primary completion date
    |
    Tecentriq (atezolizumab) • Reqorsa (quaratusugene ozeplasmid)
    8d
    Multi-omics insights for deciphering prognosis-related T cell subsets in hepatocellular carcinoma. (PubMed, Clin Transl Med)
    Our findings depicted the prognostic immune landscape of HCC by identifying distinct T cell populations and molecular interactions. DPT cells emerged as a critical biomarker for poor prognosis, and the endothelial-derived HBEGF-DPT axis could represent a potential therapeutic target.
    Journal • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • KLRB1 (Killer Cell Lectin Like Receptor B1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    8d
    Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study (clinicaltrials.gov)
    P3, N=5000, Not yet recruiting, Exelixis
    New P3 trial
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • enzalutamide • Cabometyx (cabozantinib tablet) • abiraterone acetate • zanzalintinib (XL092)